+1 (866) 450-4223 sales@dermtech.com

Clinical Collaborations

DermTech’s validated platform technology is being used to support drug discovery and
development programs focused on cancers and inflammatory diseases in clinical research trials from Phase 1-3.

Current Indications:

Alopecia Areata

Atopic Dermatitis

B-Cell Lymphoma

Cosmeceuticals

Companion & Complimentary Dx

Ewing Sarcoma

Follicular Lymphoma

GVHD

Hidradenitis Suppurativa

Lupus

Mantle Cell Lymphoma

Microbiome

Pemphigus

Psoriasis

T-cell Lymphoma

Vitiligo

Using DermTech’s proprietary technology, pharma partners can stratify and select patients based on initial skin gene expression profiles, identify biomarkers of specific diseases and disease subsets, and track and predict drug responses.

Advances in genomic analysis are revolutionizing the practice of medicine, improving patient care, enabling early disease detection, and advancing the treatment of diseases.

Growing List of Indications:

Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas. DermTech’s proprietary technology enables a variety of tests including gene expression, DNA mutation and microbiome analyses. This paradigm shifting platform uses stratum corneum tissue collected non-invasively with our Adhesive Skin Collection Kit.

PUBLICATIONS

Get In Touch.

Toll Free:
(866) 450-4223

EMAIL US